drugset / Trial / NCT00598793

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

NCT00598793

Phase 3 Completed 242 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insulin naive and failing OAD therapy.

Timeline

Start
2002-11
Primary completion
2004-03
Completion
2004-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject biphasic insulin aspart Protein / enzyme biologic
Subject insulin glargine Protein / enzyme biologic
Background Metformin Small molecule 2550 mg
Background Pioglitazone Small molecule